AKBA - Akebia Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 223.11M
Enterprise value 249.03M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.82
Price/book (mrq)N/A
Enterprise value/revenue 0.92
Enterprise value/EBITDA 34.59

Trading information

Stock price history

Beta (5Y monthly) 0.73
52-week change 3169.66%
S&P500 52-week change 34.08%
52-week high 31.6300
52-week low 30.2410
50-day moving average 30.8842
200-day moving average 30.5968

Share statistics

Avg vol (3-month) 31.72M
Avg vol (10-day) 32.87M
Shares outstanding 5185.93M
Implied shares outstanding 6N/A
Float 8168M
% held by insiders 11.28%
% held by institutions 129.15%
Shares short (14 May 2023) 44.07M
Short ratio (14 May 2023) 42.89
Short % of float (14 May 2023) 42.22%
Short % of shares outstanding (14 May 2023) 42.19%
Shares short (prior month 13 Apr 2023) 45.68M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -20.79%
Operating margin (ttm)-1.58%

Management effectiveness

Return on assets (ttm)-0.66%
Return on equity (ttm)-958.14%

Income statement

Revenue (ttm)271.03M
Revenue per share (ttm)1.47
Quarterly revenue growth (yoy)-35.00%
Gross profit (ttm)141.8M
Net income avi to common (ttm)-56.36M
Diluted EPS (ttm)-0.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)56.95M
Total cash per share (mrq)0.31
Total debt (mrq)82.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.46
Book value per share (mrq)-0.08

Cash flow statement

Operating cash flow (ttm)-69.07M
Levered free cash flow (ttm)10.03M